Project Grant R01HL176493
Award Date
4/1/25
Completion Date
1/31/29
Dollars Obligated
$633K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This $1,532,542 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate peripheral mechanisms contributing to exercise intolerance in patients with heart failure with preserved ejection fraction (HFpEF).
The key objectives are to (1) test whether abnormal locomotor skeletal muscle afferent feedback reflexes impair cardiovascular and ventilatory function during exercise in...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $653,854 to the University of Pittsburgh to conduct research into how cardiomyocyte-specific modulation of natriuretic peptide signaling pathways can improve cardiac function and reduce arrhythmia susceptibility in cardiomyopathy models. The research aims to define the roles of protein kinase G1 (PKG1), protein inhibitor of activated...
This $5,715,866 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop novel, transformative therapies to reduce the burden of pulmonary fibrosis (PF). The grant supports a multi-institutional research program consisting of 4 projects and 3 cores to investigate the mechanisms driving the initiation and early progression of pre-clinical PF. The key products and services to be delivered include:
Utilizing...
The University of Pittsburgh was awarded a $242,310 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) on June 12, 2024. The grant will support research to investigate the role of the NADPH oxidase 1 (NOX1) enzyme and AMP-activated protein kinase alpha-1 (AMPKA1) in the development of pulmonary arterial hypertension (PAH). Specifically, the project aims to determine how NOX1-induced oxidation of AMPKA1 can lead to the dysregulation...
The National Institutes of Health's Office of the Director awarded a $8,661,331 project grant under the Lung Diseases Research program (CFDA 93.838) to the Massachusetts General Hospital on June 10, 2021 for the development of interactive data portals and analytic tools to support Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) cohorts.
Key products and services delivered through Massachusetts General Hospital and several sub-awardees include an interactive data portal called the...
This $364,879 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research by Dr. Jasleen Minhas at the University of Pennsylvania to investigate patterns of heart rate and daily physical activity in patients with pulmonary arterial hypertension (PAH).
The key objectives are to: 1) identify determinants of heart rate and physical activity patterns in PAH, 2) develop novel phenotypes by...
This $480,990 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) Cardiovascular Diseases Research program (CFDA 93.837) supports research on the role of aerocytes, a specialized capillary endothelial cell population, in alveolar epithelial regeneration following acute lung injury. The research aims to investigate how aerocyte-derived signaling, particularly the R-spondin3 molecule, guides the regenerative remodeling of alveolar epithelium and establishes a...
This Project Grant award, valued at $654,367 and spanning from January 1, 2025 to December 31, 2029, was awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The award supports research by the Hugo W. Moser Research Institute at Kennedy Krieger, Inc. to investigate the neural mechanisms underlying fatigue associated with post-acute sequelae of SARS-CoV-2...
This $104,933 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to determine the role of clonal hematopoiesis of indeterminate potential (CHIP), an inflammatory aging biomarker, in cardiorespiratory fitness (CRF) and cardiometabolic responses to chronic exercise interventions. The research will evaluate whether CHIP is associated with worse baseline CRF and predicts heterogeneity in response to...
This Federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $293,188 to Vanderbilt University Medical Center to conduct the "MHOVE-PPH STUDY: Mobile Health Intervention to Improve Exercise in Pediatric Pulmonary Hypertension" over a 3-year period from May 2024 to April 2027.
The grant aims to develop and evaluate a mobile health intervention to increase physical activity and exercise capacity in...